Hypertension, Insulin Resistance, Metabolic Syndrome
Conditions
Keywords
Montmorency Tart Cherry, Anthocyanins, Polyphenols, Metabolic Syndrome, Insulin Resistance, Hypertension, Lipid Profile, Prediabetes
Brief summary
The present study examined the effect of Montmorency tart cherry juice on functional and blood-based cardio-metabolic markers in humans with Metabolic Syndrome. Participants consumed Montmorency tart cherry juice or a placebo beverage continuously for 7 days in a randomised, crossover trial. Outcome variables were measured immediately prior to supplementation and post-supplementation. Furthermore, on the 7th day of supplementation outcome variables were measured pre- and up to 5 hours post-bolus. It was hypothesised that Montmorency tart cherry juice would improve cardio-metabolic markers, particularly fasting insulin and systolic blood pressure. Furthermore, the study aimed to identify the mechanism of action for any effects of Montmorency tart cherry juice on blood pressure.
Interventions
DIETARY_SUPPLEMENTMontmorency Tart Cherry Juice
100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water. Concentrate contains no sweeteners, preservatives, flavourings or added sugar.
DIETARY_SUPPLEMENTPlacebo
Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
Sponsors
University of Hertfordshire
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Meet 3 of 5 criteria for Metabolic Syndrome based on National Cholesterol Education Program-Adult Treatment Panel III guidelines: 1. Waist Circumference: \>102cm (men), \>88cm (women) 2. Fasting Serum Triglycerides: ≥1.69 mmol.L-1 3. Fasting High Density Lipoprotein: \<1.03 mmol.L-1 (men), \<1.29 mmol.L-1 (women) 4. Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP 5. Fasting Plasma Glucose: ≥6.1 mmol.L-1
Exclusion criteria
* Smokers * Current or previous history of gastrointestinal, cardiovascular, hepatic or renal disease * Currently diagnosed with diabetes or uncontrolled hypertension (≥160/100 mmHg) * Allergy to fructose, maltodextrin or specific fruit products * Currently taking medication (such as steroids, NSAIDs, antibiotics, antihypertensive, hypoglycaemic, lipid-lowering drugs) * Currently using any nutritional or antioxidant supplement. Heavy alcohol consumption (\>14 units per week).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Fasting Insulin | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) |
| Change in Systolic and Diastolic Blood Pressure | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) |
| Change in Fasting Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL) | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) |
| Change in Fasting Glucose | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Resting Metabolic Rate | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) | — |
| Change in 24-hour Ambulatory Blood Pressure | Baseline, Post-Supplementation (7 days) | Systolic, Diastolic and Pulse Pressure will be measured |
| Change in Angiotensin Converting Enzyme Inhibition activity | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) | — |
| Change in HOMA2-IR, HOMA%S and HOMA%B | Baseline, Post-Supplementation (7 days) | Homeostatic Model Assessment of Insulin Resistance, Sensitivity and Beta-cell function |
| Change in Pulse Wave Analysis | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) | — |
| Change in Cardiac Haemodynamics | Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) | Beat-by-beat cardiac output, stroke volume, heart rate, total peripheral resistance, mean arterial pressure will be measured |
Countries
United Kingdom
Outcome results
None listed